Omnicell (OMCL) Competitors

$44.72 +0.90 (+2.05%)

Closing price 05/20/2026 04:00 PM Eastern

Extended Trading

$44.42 -0.31 (-0.68%)

As of 04:06 AM Eastern

OMCL vs. MASI, AMN, WST, HSTM, and MDRX

Should you buy Omnicell stock or one of its competitors? MarketBeat compares Omnicell with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Omnicell include Masimo (MASI), AMN Healthcare Services (AMN), West Pharmaceutical Services (WST), HealthStream (HSTM), and Veradigm (MDRX).

How does Omnicell compare to Masimo?

Masimo (NASDAQ:MASI) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

Masimo presently has a consensus price target of $180.40, suggesting a potential upside of 0.90%. Omnicell has a consensus price target of $59.86, suggesting a potential upside of 33.85%. Given Omnicell's stronger consensus rating and higher probable upside, analysts clearly believe Omnicell is more favorable than Masimo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Masimo	0 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Masimo has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Omnicell has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

In the previous week, Omnicell had 5 more articles in the media than Masimo. MarketBeat recorded 8 mentions for Omnicell and 3 mentions for Masimo. Omnicell's average media sentiment score of 0.71 beat Masimo's score of 0.04 indicating that Omnicell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Masimo	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Omnicell	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.0% of Masimo shares are held by institutional investors. Comparatively, 97.7% of Omnicell shares are held by institutional investors. 9.7% of Masimo shares are held by company insiders. Comparatively, 2.9% of Omnicell shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Masimo has a net margin of 4.90% compared to Omnicell's net margin of 1.67%. Masimo's return on equity of 31.33% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Masimo	4.90%	31.33%	13.93%
Omnicell	1.67%	4.00%	2.46%

Omnicell has lower revenue, but higher earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Masimo	$1.53B	6.13	-$151.50M	-$10.54	N/A
Omnicell	$1.18B	1.72	$2.05M	$0.44	101.64

Summary

Omnicell beats Masimo on 10 of the 17 factors compared between the two stocks.

How does Omnicell compare to AMN Healthcare Services?

Omnicell (NASDAQ:OMCL) and AMN Healthcare Services (NYSE:AMN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Omnicell has higher earnings, but lower revenue than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.72	$2.05M	$0.44	101.64
AMN Healthcare Services	$2.73B	0.38	-$95.70M	-$0.87	N/A

In the previous week, Omnicell had 2 more articles in the media than AMN Healthcare Services. MarketBeat recorded 8 mentions for Omnicell and 6 mentions for AMN Healthcare Services. Omnicell's average media sentiment score of 0.71 beat AMN Healthcare Services' score of 0.23 indicating that Omnicell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AMN Healthcare Services	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.7% of Omnicell shares are held by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are held by institutional investors. 2.9% of Omnicell shares are held by insiders. Comparatively, 1.1% of AMN Healthcare Services shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Omnicell has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market.

Omnicell has a net margin of 1.67% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.67%	4.00%	2.46%
AMN Healthcare Services	-0.95%	18.01%	5.19%

Omnicell currently has a consensus price target of $59.86, suggesting a potential upside of 33.85%. AMN Healthcare Services has a consensus price target of $25.29, suggesting a potential downside of 5.91%. Given Omnicell's stronger consensus rating and higher probable upside, equities research analysts plainly believe Omnicell is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
AMN Healthcare Services	2 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.44

Summary

Omnicell beats AMN Healthcare Services on 12 of the 16 factors compared between the two stocks.

How does Omnicell compare to West Pharmaceutical Services?

West Pharmaceutical Services (NYSE:WST) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

In the previous week, West Pharmaceutical Services had 17 more articles in the media than Omnicell. MarketBeat recorded 25 mentions for West Pharmaceutical Services and 8 mentions for Omnicell. West Pharmaceutical Services' average media sentiment score of 0.87 beat Omnicell's score of 0.71 indicating that West Pharmaceutical Services is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
West Pharmaceutical Services	7 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omnicell	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

West Pharmaceutical Services has higher revenue and earnings than Omnicell. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
West Pharmaceutical Services	$3.22B	6.70	$493.70M	$7.48	40.82
Omnicell	$1.18B	1.72	$2.05M	$0.44	101.64

West Pharmaceutical Services has a net margin of 16.85% compared to Omnicell's net margin of 1.67%. West Pharmaceutical Services' return on equity of 19.03% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
West Pharmaceutical Services	16.85%	19.03%	14.06%
Omnicell	1.67%	4.00%	2.46%

West Pharmaceutical Services has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market. Comparatively, Omnicell has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

93.9% of West Pharmaceutical Services shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 0.6% of West Pharmaceutical Services shares are owned by insiders. Comparatively, 2.9% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

West Pharmaceutical Services currently has a consensus price target of $322.89, indicating a potential upside of 5.74%. Omnicell has a consensus price target of $59.86, indicating a potential upside of 33.85%. Given Omnicell's stronger consensus rating and higher probable upside, analysts plainly believe Omnicell is more favorable than West Pharmaceutical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
West Pharmaceutical Services	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.92
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

West Pharmaceutical Services beats Omnicell on 11 of the 16 factors compared between the two stocks.

How does Omnicell compare to HealthStream?

Omnicell (NASDAQ:OMCL) and HealthStream (NASDAQ:HSTM) are both small-cap health care technology companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

In the previous week, Omnicell had 3 more articles in the media than HealthStream. MarketBeat recorded 8 mentions for Omnicell and 5 mentions for HealthStream. Omnicell's average media sentiment score of 0.71 beat HealthStream's score of 0.31 indicating that Omnicell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HealthStream	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HealthStream has lower revenue, but higher earnings than Omnicell. HealthStream is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.72	$2.05M	$0.44	101.64
HealthStream	$304.06M	2.30	$18.34M	$0.67	35.70

HealthStream has a net margin of 6.39% compared to Omnicell's net margin of 1.67%. HealthStream's return on equity of 6.47% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.67%	4.00%	2.46%
HealthStream	6.39%	6.47%	4.44%

Omnicell has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, HealthStream has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market.

97.7% of Omnicell shares are held by institutional investors. Comparatively, 69.6% of HealthStream shares are held by institutional investors. 2.9% of Omnicell shares are held by company insiders. Comparatively, 20.4% of HealthStream shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Omnicell presently has a consensus price target of $59.86, indicating a potential upside of 33.85%. HealthStream has a consensus price target of $24.00, indicating a potential upside of 0.33%. Given Omnicell's stronger consensus rating and higher possible upside, equities analysts plainly believe Omnicell is more favorable than HealthStream.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
HealthStream	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Omnicell beats HealthStream on 10 of the 17 factors compared between the two stocks.

How does Omnicell compare to Veradigm?

Omnicell (NASDAQ:OMCL) and Veradigm (NASDAQ:MDRX) are both small-cap health care technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Omnicell presently has a consensus target price of $59.86, suggesting a potential upside of 33.85%. Given Omnicell's stronger consensus rating and higher possible upside, equities analysts clearly believe Omnicell is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Omnicell has higher earnings, but lower revenue than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.72	$2.05M	$0.44	101.64
Veradigm	$1.53B	0.37	N/A	N/A	N/A

In the previous week, Omnicell had 6 more articles in the media than Veradigm. MarketBeat recorded 8 mentions for Omnicell and 2 mentions for Veradigm. Omnicell's average media sentiment score of 0.71 beat Veradigm's score of 0.00 indicating that Omnicell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradigm	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Omnicell has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Veradigm has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

97.7% of Omnicell shares are held by institutional investors. 2.9% of Omnicell shares are held by insiders. Comparatively, 2.3% of Veradigm shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Omnicell has a net margin of 1.67% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.00% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.67%	4.00%	2.46%
Veradigm	N/A	N/A	N/A

Summary

Omnicell beats Veradigm on 14 of the 15 factors compared between the two stocks.

Get Omnicell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OMCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OMCL vs. The Competition

Export

Metric	Omnicell	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.99B	$1.43B	$6.30B	$12.11B
Dividend Yield	N/A	N/A	2.80%	5.36%
P/E Ratio	101.64	64.73	20.82	25.31
Price / Sales	1.72	6.23	514.37	71.03
Price / Cash	15.84	22.71	43.18	55.00
Price / Book	1.62	5.99	9.88	6.94
Net Income	$2.05M	-$54.76M	$3.55B	$335.25M
7 Day Performance	2.10%	4.19%	-0.83%	-1.39%
1 Month Performance	21.69%	6.82%	-1.19%	0.09%
1 Year Performance	63.57%	-1.18%	33.66%	32.51%

Omnicell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OMCL Omnicell	3.8638 of 5 stars	$44.72 +2.1%	$59.86 +33.8%	+55.4%	$1.99B	$1.18B	101.64	3,580	Insider Trade
MASI Masimo	1.1332 of 5 stars	$178.50 +0.1%	$180.40 +1.1%	+14.5%	$9.34B	$1.53B	N/A	2,200
AMN AMN Healthcare Services	1.7079 of 5 stars	$30.43 +5.0%	$23.50 -22.8%	+17.3%	$1.12B	$2.73B	N/A	2,664	High Trading Volume
WST West Pharmaceutical Services	4.3877 of 5 stars	$322.30 -1.1%	$322.89 +0.2%	+41.7%	$23.03B	$3.22B	43.09	10,800	Analyst Revision
HSTM HealthStream	2.7176 of 5 stars	$23.12 -3.5%	$24.00 +3.8%	-16.5%	$700M	$304.06M	34.51	1,160	Ex-Dividend

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OMCL) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Omnicell (OMCL) Competitors

OMCL vs. MASI, AMN, WST, HSTM, and MDRX

How does Omnicell compare to Masimo?

Summary

How does Omnicell compare to AMN Healthcare Services?

Summary

How does Omnicell compare to West Pharmaceutical Services?

Summary

How does Omnicell compare to HealthStream?

Summary

How does Omnicell compare to Veradigm?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMCL vs. The Competition

Omnicell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Omnicell (OMCL) Competitors

OMCL vs. MASI, AMN, WST, HSTM, and MDRX

How does Omnicell compare to Masimo?

Do analysts prefer MASI or OMCL?

Which has more risk & volatility, MASI or OMCL?

Does the media refer more to MASI or OMCL?

Do insiders and institutionals hold more shares of MASI or OMCL?

Is MASI or OMCL more profitable?

Which has better earnings and valuation, MASI or OMCL?

Summary

How does Omnicell compare to AMN Healthcare Services?

Which has preferable valuation & earnings, OMCL or AMN?

Does the media favor OMCL or AMN?

Do institutionals & insiders hold more shares of OMCL or AMN?

Which has more risk & volatility, OMCL or AMN?

Is OMCL or AMN more profitable?

Do analysts prefer OMCL or AMN?

Summary

How does Omnicell compare to West Pharmaceutical Services?

Does the media favor WST or OMCL?

Which has stronger valuation and earnings, WST or OMCL?

Is WST or OMCL more profitable?

Which has more risk & volatility, WST or OMCL?

Do institutionals and insiders believe in WST or OMCL?

Do analysts rate WST or OMCL?

Summary

How does Omnicell compare to HealthStream?

Does the media refer more to OMCL or HSTM?

Which has preferable valuation and earnings, OMCL or HSTM?

Is OMCL or HSTM more profitable?

Which has more volatility & risk, OMCL or HSTM?

Do insiders & institutionals believe in OMCL or HSTM?

Do analysts prefer OMCL or HSTM?

Summary

How does Omnicell compare to Veradigm?

Do analysts recommend OMCL or MDRX?

Which has stronger valuation & earnings, OMCL or MDRX?

Does the media favor OMCL or MDRX?

Which has more volatility & risk, OMCL or MDRX?

Do institutionals & insiders hold more shares of OMCL or MDRX?

Is OMCL or MDRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMCL vs. The Competition

Omnicell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools